Evolution, classification and genotypes of HCV: the clinical significance of determining HCV genotypes

International Journal of Medical Science

© 2019 by SSRG - IJMS Journal

Volume 6 Issue 6

Year of Publication : 2019

Authors : Nahida Sultana, Mohammad Razib Ahsan, Umme Shahera, Mariya Kibtiya Sumiya, Razoanul Haque

10.14445/23939117/IJMS-V6I6P103

How to Cite?

Nahida Sultana, Mohammad Razib Ahsan, Umme Shahera, Mariya Kibtiya Sumiya, Razoanul Haque, "Evolution, classification and genotypes of HCV: the clinical significance of determining HCV genotypes," SSRG International Journal of Medical Science, vol. 6,  no. 6, pp. 11-16, 2019. Crossref, https://doi.org/10.14445/23939117/IJMS-V6I6P103

Abstract:

Chronic hepatitis C, attributed to infection with hepatitis C virus (HCV), is a global health problem. The overall prevalence of viral hepatitis worldwide is estimated to be 3.8% with over 185 million people infected with HCV. Clinically, HCV can establish a persistent, chronic infection contributing to progressive liver disease, including cirrhosis and hepatocellular carcinoma (HCC), requiring intensive treatment regimens, possible liver transplantation and long-term care. Due to the chronic nature of HCV infection and the tremendous burden on healthcare resources, clinicians and laboratorians have looked for key epidemiological, pathological and viral characteristics that may provide insight into disease progression, severity and response to therapy to permit the administration of effective therapeutic regimens as well as long-term management of infected individuals. Determination of viral genotype has been identified as one parameter that could provide direction in the clinical management of patients with chronic HCV infections. The following review provides background on determination of HCV genotypes and the relevance of viral genome characterization in the current clinical setting.

Keywords:

Hepatitis C virus, Evolution, Classifications, Genotypes

References:

[1] Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology; 42(4): 962-73.
[2] Simmonds P (2004). Genetic diversity and evolution of hepatitis C virus–15 years on. Journal of General Virology; 85(11): 3173-88.
[3] Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, Simmonds P(1997). The origin of hepatitis C virus genotypes. Journal of General Virology; 78(2): 321-8.
[4] Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, Korber BT, Bhattacharya T, Guedj J, Parrish EH, Hahn BH, Shaw GM (2012). Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog; 8(8): e1002881.
[5] Kato N, Ootsuyama Y, Sekiya H, Ohkoshi S, Nakazawa T, Hijikata M, Shimotohno K (1994). Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. Journal of virology; 68(8): 4776-84.
[6] Halfon P, Sarrazin C (2012). Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?. Liver International; 32(s1): 79-87.
[7] Simmonds P (2013). The origin of hepatitis C virus. In Hepatitis C Virus: Molecular Virology to Antiviral Therapy. Springer Berlin Heidelberg: 1-15. [8] Simmonds P, Mellor J, Sakuldamrongpanich T, Nuchaprayoon C, Tanprasert S, Holmes EC, Smith DB (1996). Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: comparison with classifications based upon sequence similarity. Journal of General Virology; 77(12): 3013-24. [9] Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology; 59(1): 318-327.
[10] Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC (1994).Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. Journal of General Virology; 75(5): 1053-1061.
[11] Power JP, Lawlor E, Davidson F, Holmes EC, Yap PL, Simmonds P. (1995). Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. The Lancet; 345(8959): 1211-1213.
[12] Höhne M, Schreier E, Roggendorf M (1994). Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Archives of virology; 137(1-2): 25-34.
[13] Bronowicki JP, Venard V, Botté C, Monhoven N, Gastin I, Choné L, Hudziak H, Rhin B, Delanoë C, LeFaou A, Bigard MA (1997). Patient-to-patient transmission of hepatitis C virus during colonoscopy. New England journal of medicine; 337(4): 237-240.
[14] Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (1996). Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Annals of internal medicine; 125(8): 634-9.57.
[15] Berg T, Hopf U, Stark K, Baumgarten R, Lobeck H, Schreier E (1997). Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. Journal of hepatology; 26(3): 484-91.
[16] Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D (1995). Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. Journal of Infectious Diseases; 171(6): 1607-10.
[17] Watson JP, Brind AM, Chapman CE, Bates CL, Gould FK, Johnson SJ, Burt AD, Ferguson J, Simmonds P, Bassendine MF (1996). Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut. 1996; 38(2): 269-76.
[18] Weiner AJ, Thaler MM, Crawford K, Ching K, Kansopon J, Chien DY, Hall JE, Hu F, Houghton M. A unique (1993). predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. Journal of virology; 67(7): 4365-8.
[19] Zein NN (2000). Clinical significance of hepatitis C virus genotypes. Clinical microbiology reviews; 13(2): 223-35.
[20] Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, Rumi MG, Houghton M, Fiaccadori F, Ferrari C (1996). Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. Journal of Clinical Investigation; 98(3): 706.
[21] Amoroso P, Rapicetta M, Tosti ME, Mele A, Spada E, Buonocore S, Lettieri G, Pierri P, Chionne P, Ciccaglione AR, Sagliocca L (1998) . Correlation between virus genotype and chronicity rate in acute hepatitis C. Journal of hepatology; 28(6): 939-44.
[22] Zein NN, Rakela J, Persing DH (1995). Genotype-dependent serologic reactivities in patients infected with hepatitis C virus in the United States. In Mayo Clinic Proceedings; 70(5): 449-452.
[23] Dhaliwal SK, Prescott LE, Dow BC, Davidson F, Brown H, Yap PL, Follett EA, Simmonds P (1996). Influence of viraemia and genotype upon serological reactivity in screening assays for antibody to hepatitis C virus. Journal of medical virology; 48(2): 184-90.
[24] Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K (1996). The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology; 23(4): 695-9.
[25] Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M (1997). Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology; 25(3): 754-8.
[26] Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A (1997). Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus‐related cirrhosis. Hepatology; 25(1): 211-5.
[27] Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM (2009). Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLOS one; 4(12): e8209.
[28] Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F (2016). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine; 373(27): 2599-607.
[29] Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ (2015). Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. New England Journal of Medicine; 373(27): 2608-17.
[30] EASL Recommendations on Treatment of Hepatitis C 2016 (2016). J Hepatol, http://dx.doi.org/10.1016/j. jhep.2016.09.001.
[31] Pawlotsky JM (2003). Hepatitis C virus genetic variability: patho-genic and clinical implications. Clinical Liver Disease; 7:45–66.
[32] Houghton M (2000). Strategies & prospects for vaccination against the hepatitis C viruses. Current Topics in Microbiology & Immunology; 242:327–339.
[33] Howard CR (2002). Hepatitis C virus: clades and properties. Journal of Gastroenterology & Hepatology 17(Suppl): S468–470.
[34] Arribillaga L, de Cerio AL, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-Romero O, Borras-Cuesta F, ParanhosBaccala G, Prieto J, Ruiz J & Lasarte JJ (2002). Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine; 21:202–210.
[35] Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E & Rosen HR (2003). Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology; 37:577–589.
[36] Matsui M, Moriya O & Akatsuka T (2003). Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine; 21:1629–1639.
[37] Park SH, Yang SH, Lee CG, Youn JW, Chang J & Sung YC (2003). Efficient induction of T helper 1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine; 21:4555–4564.
[38] Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, Ray SC & Thomas DL (2004). Cross-genotype immunity to hepatitis C virus. Journal of Virology; 78:1575–1581
[39] Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM & Walker CM (2003). HCV persistence and immune evasion in the absence of memory T cell help. Science; 302:659–662.